Stock comparison
Becton, Dickinson and
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BDX
Becton, Dickinson and
Market cap
$53.49B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BDX | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 49D | 65C | GMAB |
| Benjamin Graham | 57C | 64C | GMAB |
| Philip Fisher | 36D | 48D | GMAB |
| Peter Lynch | 15F | 25F | GMAB |
| Joel Greenblatt | 40D | 76B | GMAB |
| Charlie Munger | 39D | 68C | GMAB |
| Terry Smith | 39D | 71C | GMAB |
Side-by-side metrics
| Metric | BDX | GMAB |
|---|---|---|
| Market cap | $53.49B | $16.5B |
| P/E (TTM) | 35.3x | 6.2x |
| EV/EBIT | 26.5x | 12.0x |
| ROIC (TTM) | 4.1% | 43.78% |
| Gross margin | 46.48% | 93.88% |
| Net margin | 5.33% | 18.23% |
| Revenue CAGR 5y | 3.37% | -18.45% |
| EPS CAGR 5y | -4.15% | -23.48% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 2.45% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BDX leads on
- Revenue CAGR 5y3.37%vs -18.45%+118%
- Dividend yield2.45%vs 0.0%+100%
- EPS CAGR 5y-4.15%vs -23.48%+82%
- Market cap$53.49Bvs $16.5B+69%
GMAB leads on
- ROIC (TTM)43.78%vs 4.1%+91%
- Debt / Equity0.1xvs 0.7x+90%
- P/E (TTM)6.2xvs 35.3x+83%
- Net margin18.23%vs 5.33%+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.